Table 2.
Patient characteristics and results of spontaneous sputum sample cultures.
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Sex | F | F | M |
| Age (yr) | 23 | 39 | 35 |
| Antibiotic therapy | Linezolid Aztreonam Colistin |
Linezolid Tobramycin Colistin |
Ciprofloxacin Trimethoprim-sulfamethoxazole Colistin |
| Pathogensa |
Escherichia coli (2×106 CFU/ml) Staphylococcus aureus (4.105 CFU/ml) Candida albicans* |
Staphylococcus aureus (2.104 CFU/ml) Pseudomonas aeruginosa (3.106 CFU/ml) Aspergillus flavus* Candida dubliniensis* |
Morganella morganii (2×104 CFU/ml) Proteus mirabilis (8×102 CFU/ml) Staphylococcus aureus (7×105 CFU/ml) Mycobacterium avium* Trichosporon mycotoxinivorans* Aspergillus fumigatus* Candida albicans* |
Sputum pathogens have been cultured, identified and quantified according to national guidelines for the microbiological analysis of sputum samples of CF patients (Société Française de Microbiologie, 2018).
Species load were not determined during analysis.